In plain words
Three of the four small randomized trials found lower fatigue with rhodiola extract than with a placebo. The fourth suggested this happens only under certain stressful conditions. A 2012 review, which may include these trials, judged the studies it read too weak to say either way.
The short answer
Three of the four randomized trials found lower fatigue than with placebo: one dose in 161 cadets (2003), 576 mg a day for 28 days in 60 adults with stress-related fatigue (2008), and a low dose for 20 days (2000; the ledger has no n). The fourth, 56 people on one low-dose tablet a day for two weeks, suggested less fatigue only under certain stressful conditions (2000). A before-after study of 100 people found fatigue lower after 8 weeks at 2 × 200 mg, a possible effect. Certainty is very low: a 2012 review that may include these trials judged all its studies at high or unclear risk of bias.
Where the evidence sits
Less fatigue
Evidence insufficient
Less fatigue only under some stress
■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data
Who says what
| Source | Finding | Design | People | Dose and length | Funding and independence |
|---|---|---|---|---|---|
| Shevtsov et al., 2003 | Less fatigue | Randomized trial | 161 cadets | Once | Not in ledger |
| Olsson et al., 2008 | Better burnout score | Randomized trial | 60, stress-related fatigue | 576 mg daily, 28 days | Not in ledger |
| Spasov et al., 2000 | Better; dose probably low | Randomized trial | Not in ledger | Low dose, 20 days | Not in ledger |
| Darbinyan et al., 2000 | Only under certain stress | Randomized trial | 56 | Low dose, 2 weeks | Not in ledger |
| Lekomtseva et al., 2017 | Lower than start | Before-after, uncontrolled | 100, chronic fatigue | 2×200 mg, 8 weeks | Not in ledger |
| Ishaque et al., 2012 | Insufficient evidence | Review; may include trials above | None | Not in ledger | Not in ledger |
| EBSCO Research Starters | Supportive; doubts setting | Encyclopedia describing trials | None | Not in ledger | Not in ledger |
Less fatigue
Better burnout score
Better; dose probably low
Only under certain stress
Lower than start
Insufficient evidence
Supportive; doubts setting
What did placebo trials find?
Shevtsov and colleagues (2003) gave 161 cadets under stress one dose of SHR-5 extract (2 or 3 capsules) or a placebo:
This was statistically highly significant (p < 0.001) for both doses
Olsson and colleagues (2008) gave 60 adults with stress-related fatigue 576 mg a day or a placebo for 28 days:
significant effects of the SHR-5 extract in comparison with the placebo were observed in Pines' burnout scale
Did dose or setting matter?
Spasov and colleagues (2000) gave a low dose for 20 days; the ledger has no n for this trial. They concluded that
the study drug gave significant results compared to the placebo group but that the dose level probably was suboptimal.
Darbinyan and colleagues (2000) gave 56 people one low-dose tablet a day for two weeks:
These results suggest that RRE can reduce general fatigue under certain stressful conditions.
Does it last past 28 days?
Lekomtseva and colleagues (2017) gave 100 people with prolonged or chronic fatigue 2 × 200 mg for 8 weeks, with no control group, and found fatigue significantly lower at week 8 than at the start:
The greatest change was observed after 1 week of treatment.
How do reviewers read the trials?
Ishaque and colleagues (2012) reviewed 11 studies, which may include the trials above, rating all at high or unclear risk of bias:
Two of six trials examining physical fatigue in healthy populations report R. rosea to be effective as did three of five RCTs evaluating R. rosea for mental fatigue.
EBSCO Research Starters notes that the supporting trials come from former Soviet republics with a pattern of overly positive results:
only if confirmation is obtained in a more reliable setting can rhodiola be considered to have real supporting evidence behind it.
Why the sources disagree
The trials differ in people and span: cadets after one dose, adults with stress-related fatigue over 28 days, and people with chronic fatigue over 8 weeks, compared only with their own starting point. Spasov's authors thought their dose too low. Ishaque and EBSCO re-read studies that may include the trials above: Ishaque weighs trial quality, and EBSCO doubts where the trials were run. The ledger has no funding information for any of them.
What would settle it
An independent, pre-registered, placebo-controlled trial of a standardized extract at a fixed dose for at least 12 weeks in adults with stress-related fatigue, run outside the former Soviet republics, scoring fatigue on a validated scale at 1, 4 and 12 weeks and 4 weeks after stopping. A matching result from a second group would raise certainty.
How this page was made
The 7 sources are five fatigue studies and one systematic review from a PubMed literature search, plus the EBSCO Research Starters summary. Studies of exercise and depression were left out because they measured other outcomes. Every claim was copied word for word into the Longevity Circle ledger and checked against the original text, and a person approved each one. Certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.
Changelog: 23 Sep 2026, first version, 7 sources.
